providing mechanistic insights into the combinatorial effects of TNIK and CDK9 inhibition and offering a new understanding of NCB-0846 and CDK9 inhibitor function. Our findings identified the ...

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer ...

Alsfouk et al. (Alsfouk et al., 2024) employed a computer-assisted design strategy to identify potential CDK9 and CYP3A4 inhibitors by using a predictive QSAR model and in silico synthesis. Molecular ...

These data are consistent with previous GPS trials. In the Phase 2 study in AML patients in second complete remission, the median overall survival of GPS-treated patients was 21 months versus 5.4 ...

The Company is also developing SLS009 (formerly GFH009) - potentially the first and best-in-class differentiated small molecule CDK9 inhibitor with reduced toxicity and increased potency compared ...

SELLAS focuses on developing innovative cancer therapies, including their lead candidate GPS, which targets the WT1 protein, and SLS009, a small molecule CDK9 inhibitor. SELLAS Life Sciences has ...

By mid-2024 the Food and Drug Administration had approved 81 small-molecule kinase inhibitors targeting greater than 30 kinases, providing substantial clinical benefits for patients with cancer and ...

SELLAS Life Sciences Group, Inc.’s SLS share price has dipped by 17.02%, which has investors questioning if this is right ...